(PRPH) Needs Immediate Attention After Today's Huge Breaking News (Potential Squeeze Nears?)

PRPH just dropped huge news this morning. (PRPH) Needs Immediate Attention After Today's Huge Breaking News (Potential Squeeze Nears?) May 8th Dear Reader, PRPH just dropped huge news this morning. Making a game-changing hire, all eyes could soon turn to PRPH today. Check out why: ProPhase Labs hires Dr. Matthew Halpert to Drive Company’s Key Therapeutic and Diagnostic Oncology Programs GARDEN CITY, NY, May 08, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced that Dr. Matthew Halpert has been hired as a full-time consultant to drive the Company’s key therapeutic and diagnostic programs forward which will comprise the backbone of ProPhase’s efforts in both advanced cancer therapeutics and targeted cancer diagnostics. Dr. Halpert will assist with several ongoing programs at ProPhase BioPharma (PBIO) including Linebacker-1 initiatives as a cancer mono-therapy as well as to be developed as a potential co-therapy with multi-Bn-dollar drugs like Doxorubicin. LB-1 is currently going into xenograft (mouse) studies in collaboration with the Dana Farber Cancer Institute and Harvard University scientists with the goal of completing a Phase 1 human clinical trial in 2024. Dr. Halpert will also assist with the BE-Smart Esophageal Cancer Test that is expected to advance into validation studies by Q4 2023 for research use only (RUO) testing and broad commercialization with CPT codes in early 2024. Dr. Halpert will work closely with our ProPhase team in finalizing human clinical trials for Equivir, a broad-based anti-viral to be marketed as a dietary supplement that is expected to be commercialized by Q4 2023. Dr. Halpert will also assist the ProPhase team on other new and exciting programs which will be announced at a later date as they advance in pre-clinical testing. ... “Dr. Halpert has a unique perspective and strong track record as an objective and well-regarded scientist. He also understands how to execute along the pathway toward clinical inclusion and FDA approvability with an unmatched passion,” praised Ted Karkus, CEO of ProPhase Labs. “He will be working very closely with our team to expedite a cutting-edge Esophageal Cancer Test which has multi-Bn-dollar potential and could be commercialized with CPT insurance codes in potentially less than 12 months, the multi-faceted Linebacker cancer treatment, and Equivir as a broad based anti-viral option (OTC/dietary supplement and Rx).” [Read the full article here.]( On the heels of this breaking news, PRPH continues to [trade above]( its 50-Day Simple Moving Average (SMA) and its 13-Day Exponential Moving Average. With it climbing towards its 200-Day SMA since the start of May, a potential squeeze could be on the horizon. And with a 52-week high over $15 and a $20 analyst target from Diamond Equity Research, a potential squeeze could really turn up the heat on this Nasdaq breakout idea. Take a moment to get PRPH on radar this morning and read my initial report below. ----- Biotech companies. Often involved in the development and commercialization of new drugs, therapies, and medical devices, their existence could lead to revolutionizing the healthcare industry. These innovative products have the potential to generate significant revenue and pro-fits. These companies develop drugs or therapies that address unmet medical needs or that have the potential to become blockbuster drugs that can generate significant buzz. Another reason why revenue generating Biotechs are worth researching is the potential for long-term growth. The healthcare industry is one of the largest and fastest-growing industries in the world. As the global population continues to age, demand for healthcare products and services is expected to increase. Though these are overarching reasons to watch Biotech companies closely, I've uncovered a Nasdaq profile that has even more going for it. And when you realize this breakout idea has an analyst $20 target providing over 100% potential upside, a low float, a forward-thinking, revenue generating company CEO, and an upcoming Q1 fi-nan-cials announcement, you'll understand quickly why this Nasdaq needs to be on radar now. Drop everything and pull up: *ProPhase Labs, Inc. (PRPH)* ProPhase Labs, Inc. is a next-generation biotech, genomics and diagnostics company with the goal of achieving a healthier world with bold action and the power of insight. The company is revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game-changer diagnostics and therapeutics in the fight against cancer. And right now, PRPH has several potential catalysts to soak in right now. Here's what to know: No. 1 - An Impressive $20 Target From Diamond Equity Research Signals Significant Upside Potential No. 2 - Another Low Float Idea Provides Explosive Volatility Potential Once Again No. 3 - Major Update On Linebacker-1 Shares Company's IP Could Be Used As An Effective Mono-therapy No. 4 - Company CEO Named Top 10 Most Innovative Healthcare Leaders To Watch In 2023 No. 5 - Q1 Financials To Be Announced This Week (Huge Spark Coming?) But more on these in a second... The Five Divisions Of ProPhase Labs (PRPH) Nebula Genomics - The pioneers and leader in Whole Genome Sequencing with one of the most accurate, highest quality and price competitive solutions on the market. - Offering deep insights for consumers, universities, and the healthcare industry with best-in-class tools and interpretation capabilities. ProPhase Diagnostics - State-of-the-art diagnostic laboratory services with a complete CLIA clinical lab offering, to include Chemistry, Immunoassay, Upper Respiratory, Hematology, Hemostasis and Urinalysis. - Delivered millions of highly accurate Upper Respiratory laboratory diagnostics, including PCR, antigen and flu tests in our state-of-the-art CLIA laboratories. ProPhase Biopharma - Developing groundbreaking compounds and products. - Licensing and developing with the goal of commercializing Equivir (dietary supplement) and Equivir G (Rx), two broad based anti-virals, as well as Linebacker LB-1 and LB-2, two small molecule PIM kinase inhibitors for cancer treatment. Pharmaloz Manufacturing, Inc. - 30+ years of OTC manufacturing services and consumer healthcare product development from non-GMO, Organic and/or Natural-based cough drops and lozenges for over-the-counter drugs to dietary supplement products. TK Supplements - Clinically-backed consumer products promoting better health, energy, and sexual vitality available online, Walmart, Walgreens, CVS, Rite-Aid and more. ProPhase Biopharma IP Equiver ProPhase has the exclusive worldwide rights to develop and commercialize patented Equivir and Equivir G (Rx), proprietary compounds which have shown to have potential activity against certain viruses associated with serious viral outbreaks. Linebacker ProPhase has the exclusive worldwide rights to develop and commercialize patented Linebacker LB1 and LB2 in the following fields: cancer, inflammatory diseases or symptoms, memory-related syndromes, diseases or symptoms, including dementia and Alzheimer's Disease. LB1 and LB2 are proprietary compounds which have shown in preliminary in-vitro screening tests to have potential applicability to Cancer as a co-therapy, Bacterial and viral infections, Neurological, Diabetes and Pain modulation. Summary [Company Website.]( [Company Presentation.]( ----- And as I mentioned above, PRPH has several potential breakout catalysts of note. Check them out: No. 1 PRPH Potential Catalyst - An Impressive $20 Target From Diamond Equity Research Signals Significant Upside Potential This month [Diamond Equity Research]( analyst, Hunter Diamond, tagged PRPH with a $20 price target. From Friday's closing valuation, that provides PRPH with over 100% potential upside. Here's some key highlights from the report: Diagnostics Business Enabling Pivot Toward Niche and Emerging Business Segments: ProPhase's strategic evolution from a predominantly diagnostics-centric company to a multifaceted healthcare organization is underscored by its ability to capitalize on the success and cash generation of its diagnostics division. By investing in and growing healthcare companies such as genomics and biopharma, the company expands its market presence and fosters revenue diversification. The company's management is ambitiously striving to transform ProPhase Labs into an all-encompassing healthcare powerhouse, with diagnostics and genomics pinpointing disease origins, contract manufacturing delivering top-tier production capabilities, and the biopharma division driving the development of cutting-edge therapies and treatments. Solid Fi-nan-cial Performance Showcasing Substantial Progress: The company reported strong growth across all its major business divisions for the year ended 2022. In 2022, ProPhase Labs reported revenue of $122.64Mn, a significant increase from the $79.04Mn recorded in 2021. This translates to a year-over-year (y-o-y) growth rate of 55.16%. In 2022, the diagnostics business itself experienced a 63.3% revenue growth, mainly due to increased CV-19 testing volumes in response to the spread of the Omicron variant. Other divisions, such as contract manufacturing and genomics, have also reported impressive growth numbers. We anticipate a contraction in diagnostics revenue for 2023 and 2024 due to changing market dynamics. To offset this, ProPhase is focusing on growth in BioPharma, Contract Manufacturing, and Genomics divisions. The BioPharma division aims to fully commercialize its esophageal cancer test by H1 2024, while Contract Manufacturing and Genomics divisions are expanding their client base and distribution channels. Valuation: The market has been conservative in valuing ProPhase, possibly undervaluing its potential and expertise across multiple segments due to a lack of understanding of the unique strengths and synergies between divisions. The genomics business and esophageal pre-cancer test operate in promising markets with Bn-dollar opp's. The management remains strongly optimistic about its genomics business and expects over 100% growth in 2023. These businesses are regarded as somewhat de-risked, given their exceptional value proposition and the overall market undervaluation of the company. With its impressive competitive positioning, exceptional product offerings, and tremendous growth potential within the genomics market, it can be reasonably argued that Nebula, as an independent entity, has the potential to command a valuation in the range of $80-$120Mn. Furthermore, the company’s Equivir and Linebacker portfolios are supported by a strong sound scientific background and present high upside optionality in terms of shareholder value creation. We assessed the company's value at around $344Mn or $20.00 per share using a combination of DCF and SOTP valuation methodologies, allocating equal weightage to both approaches. ... [Read the full report here.]( ----- No. 2 PRPH Potential Catalyst - Another Low Float Idea Provides Explosive Volatility Potential Once Again According to the [Yahoo Finance]( website, PRPH has a fairly low float. The website reports this profile to have approximately 13.11Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could more positive company news in the first half of 2023 provide a near term spark? ----- No. 3 PRPH Potential Catalyst - Major Update On Linebacker-1 Shares Company's IP Could Be Used As An Effective Mono-therapy ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its progress and development strategy for Linebacker-1 (LB-1). Linebacker is a small molecule, multi-kinase inhibitor that is being developed by the Company’s wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), as a potential mono-therapy and co-therapy option for hard-to-treat cancers. Originally viewed as a co-therapy, the pre-clinical data generated has given PBIO reason to believe that LB-1 will also be very effective as a mono-therapy. In Q1 of 2023, ProPhase collaborated with Eurofins, a globally recognized leading drug discovery company, to execute an in-depth analysis (KINOMEscan™ Profiling Service) of Linebacker-1 to determine how many cancer-relevant kinases were affected by Linebacker-1 out of a possible 468 enzymes. ProPhase was excited to learn that numerous critically important kinase targets were inhibited more than 99%. Some of the most inhibited pathways are those well known to promote tumorigenesis, such as the phosphoinositide 3-kinase family (e.g., PIKfyive, PIP5k1 and 2) and the mitogen-activated protein kinase family (e.g., MEK3, 4, and 5). Importantly, the Eurofins analysis revealed several unique targets affected by Linebacker-1 that cancer research organizations highlight as critically important, for which no other pharmaceutical company has developed drugs to treat. We believe the unique interplay of Linebacker with multiple cancer-dependent pathways will be a true differentiator within current treatment paradigms. ... “The two-year bear market for microcap companies has led to some phenomenal opp's in the biotech and life sciences space and specifically for our company,” said Ted Karkus, CEO of ProPhase Labs. “The fi-nan-cial success of our diagnostic business over the past two years enabled us to acquire some fantastic under-valued assets, while strengthening our company’s core infrastructure. We are confident that we will be able to leverage this infrastructure and platform to develop our new, exciting initiatives with multi-Bn-dollar potential, including our development of the Linebacker portfolio. These continuing positive preliminary results from the Linebacker-1 pre-clinical studies continue to bolster our confidence and support the new directions that we are taking with our company with the goal of continuing to significantly grow the underlying value. We look forward to providing updates in the coming weeks on additional Linebacker pre-clinical studies that are being conducted in parallel. We also look forward to providing updates on other strategic initiatives that have so much potential.” [Read the full article here.]( ----- No. 4 PRPH Potential Catalyst - Company CEO Named Top 10 Most Innovative Healthcare Leaders To Watch In 2023 ProPhase Labs CEO Ted Karkus Named One of Inc Magazine’s 10 Most Innovative Healthcare Leaders to Watch in 2023 Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, is pleased to announce that Ted Karkus, CEO, has been named one of Inc Magazine’s 10 Most Innovative Healthcare Leaders to Watch in 2023. The annual listing represents dynamic healthcare leaders redefining the world with their innovative products and leadership. Mr. Karkus was recognized by Inc Magazine for his visionary leadership in the healthcare industry, as well as his dedication to driving innovation and improving patient outcomes. Under his guidance, ProPhase Labs has rapidly evolved from a legacy over-the-counter healthcare products and supplements company to a diversified, next-generation biotech, genomics and diagnostics company with multiple new products and subsidiaries. In the article, Mr. Karkus was highlighted for his leadership stewarding ProPhase Labs through the coronavirus pandemic, and his efforts to bring cutting-edge technologies and therapies to the healthcare industry through subsidiaries ProPhase Diagnostics, ProPhase BioPharma and Nebula Genomics. Mr. Karkus was instrumental in ProPhase’s quick pivot into the CV-19 testing business at the onset of the pandemic, generating over $200Mn in revenue over the past few years and fueling the company’s long-term growth and diversification strategies. Mr. Karkus commented, “I am honored to be recognized by Inc Magazine as one of the 10 Most Innovative Healthcare Leaders to Watch for 2023. This recognition is a testament to the hard work and dedication of the entire ProPhase Labs team, and I look forward to continuing to drive innovation and improve patient outcomes in the years ahead. With Nebula Genomics, and the potential game changer diagnostics and therapeutics we are developing, including our BE-Smart Esophageal Cancer Test, Linebacker cancer compounds, and broad based Equivir anti-virals, as well as our new fully diversified, state-of-the-art clinical lab and genomics testing lab, I promise that we are just getting started and that there is a lot more to come!” ... [Read the full article here.]( ----- No. 5 PRPH Potential Catalyst - Q1 Financials To Be Announced This Week (Huge Spark Coming?) ProPhase Labs to Host First Quarter 2023 Fi-nan-cial Results Conference Call on Thursday, May 11, 2023 at 11:00 a.m. Eastern Time GARDEN CITY, NY, May 04, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, will hold a conference call on Thursday, May 11, 2023, at 11:00 a.m. Eastern time to discuss its results for the first quarter ended March 31, 2023. A press release detailing these results will be issued prior to the call. ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted Karkus, will host the conference call, followed by a question-and-answer period. [Read the full article here.]( ----- PRPH Recap - 5 Must-Know Potential Breakout Catalysts Right Now No. 1 - An Impressive $20 Target From Diamond Equity Research Signals Significant Upside Potential No. 2 - Another Low Float Idea Provides Explosive Volatility Potential Once Again No. 3 - Major Update On Linebacker-1 Shares Company's IP Could Be Used As An Effective Mono-therapy No. 4 - Company CEO Named Top 10 Most Innovative Healthcare Leaders To Watch In 2023 No. 5 - Q1 Financials To Be Announced This Week (Huge Spark Coming?) ----- Coverage is officially initiated on PRPH. When time permits, do this: Get PRPH on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 5/7/23 and ending on 5/9/23 to publicly disseminate information about (PRPH) via Website, Email and SMS. SWN Media LLC was paid twenty-two thousand five hundred and three cents USD via bank wire transfer. We own zero shares of (PRPH). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 05/09/2023 and ending on 05/09/2023 to publicly disseminate information about (PRPH:US) via digital communications. We have been paid an additional fifteen thousand dollars USD. To date we have been paid thirty seven thousand five hundred dollars USD to disseminate information about (PRPH:US) via digital communications. We own zero shares of (PRPH:US). TD Media LLC was compensated a total of ninety-seven thousand five hundred USD to disseminate information about 3 different profiles including (PRPH:US), (CETX:US) and (TRNR:US). [( Fierce | 401 W. Atlantic Ave, Ste R10 Unit #271, Delray Beach, FL 33444 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net